Loading company filing…
Find a company. Follow its revenue through costs and profit.
Coverage includes separate ticker and security records; counts are not unique companies.
Sankey diagram of Moderna Inc. A complete text table follows the diagram.
The mRNA pipeline spans respiratory disease, cancer and rare disorders, but today's commercial base remains concentrated in two COVID vaccines
Swipe to explore
Product flows are exact reported amounts. Other Revenue is the arithmetic difference between reported total revenue and reported net product sales and includes non-product activities such as collaboration and stand-ready manufacturing revenue.
Labels and narrative explain the filing. A category marked “arithmetic bridge” or “residual” is calculated from reported totals, rather than a separately reported line.
| Category | Stage | Value | Notes |
|---|---|---|---|
| Moderna revenue | 1 | $389M | Up 260% from the prior-year quarter |
| Commercial vaccine sales | 2 | $352M | 91% of total revenue |
| Other revenue | 2 | $37M | Manufacturing, collaboration and related revenue |
| COVID vaccines | 3 | $345M | Spikevax and mNEXSPIKE |
| RSV vaccine | 3 | $7M | mRESVIA |
| From | To | Value |
|---|---|---|
| Moderna revenue | Commercial vaccine sales | $352M |
| Moderna revenue | Other revenue | $37M |
| Commercial vaccine sales | COVID vaccines | $345M |
| Commercial vaccine sales | RSV vaccine | $7M |